exercise and glp 1 GLP-1 Program: Enhance Strength & Combat Muscle Loss GLP-1 vs. Exercise: Two Paths

If you have Medicare or Medicaid Check Lilly Cares Patient Assistance

DOI: 10.1038/s41591-022-02026-4

By the end of the study, the ICP in exenatide users decreased by 5.6 3.0 cmCSF compared with controls ( P = .058)

Protection against stroke with glucagon-like peptide-1 receptor agonists: A comprehensive review of potential mechanisms

ATTAIN-1 (NCT05869903) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of orforglipron at various doses to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes